公开(公告)号：US12221406B2

公开(公告)日：2025-02-11

申请号：US17627214

申请日：2020-07-15

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Shijun Zhang

IPC: C07D333/24 ,  A61P37/02 ,  C07C311/37 ,  C07C311/46 ,  C07D207/20 ,  C07D209/14 ,  C07D233/26 ,  C07D241/12 ,  C07D249/04 ,  C07D277/56 ,  C07D277/593 ,  C07D285/06 ,  C07D307/64 ,  C07D317/62 ,  C07D409/12 ,  C07D413/12

Abstract: Scaffold compounds are used to design small molecule compounds and structure-activity relationship studies identify inhibitors of inflammation. Methods include pharmaceutical compositions of the small molecule compounds to inhibit, prevent and treat diseases and conditions associated with inflammation, including multiple sclerosis, Alzheimer's disease, acute myocardial infarction, traumatic brain injury and autoinflammatory diseases.

公开(公告)号：US20240425547A1

公开(公告)日：2024-12-26

申请号：US18809687

申请日：2024-08-20

Applicant: Siemens Medical Solutions USA, Inc.

Inventor： Eric Wang ,  Hartmuth C. Kolb ,  Anna Katrin Szardenings ,  Changhui Liu ,  Joseph C. Walsh ,  Gang Chen ,  Anjana Sinha ,  Dhanalakshmi Kasi ,  Chul Yu ,  Umesh B. Gangadharmath ,  Wei Zhang ,  Tieming Zhao ,  Vani P. Mocharla

IPC: C07K5/02 ,  A61K38/00 ,  A61K51/04 ,  A61K51/08 ,  C07D207/16 ,  C07D209/48 ,  C07D213/81 ,  C07D213/82 ,  C07D233/78 ,  C07D233/96 ,  C07D239/60 ,  C07D249/04 ,  C07D249/06 ,  C07D251/30 ,  C07D263/34 ,  C07D277/56 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07K5/062 ,  C07K5/072

Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

公开(公告)号：US20240368129A1

公开(公告)日：2024-11-07

申请号：US18657122

申请日：2024-05-07

Applicant: NodThera Limited

Inventor： David HARRISON ,  Alan Paul WATT ,  Mark G. BOCK

IPC: C07D403/12 ,  C07D231/38 ,  C07D237/20 ,  C07D239/42 ,  C07D249/04 ,  C07D249/14 ,  C07D261/14 ,  C07D277/52 ,  C07D285/135 ,  C07D307/66 ,  C07D401/12 ,  C07D405/12 ,  C07D471/08

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

公开(公告)号：US20240343696A1

公开(公告)日：2024-10-17

申请号：US18576379

申请日：2022-07-05

Applicant: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.

Inventor： Shmuel BEN-SASSON Z”L ,  Einav GROSS

IPC: C07D249/12 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4196 ,  A61P35/00 ,  A61P39/00 ,  C07D231/12 ,  C07D231/18 ,  C07D233/64 ,  C07D233/84 ,  C07D249/04

CPC classification number: C07D249/12 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4196 ,  A61P35/00 ,  A61P39/00 ,  C07D231/12 ,  C07D231/18 ,  C07D233/64 ,  C07D233/84 ,  C07D249/04

Abstract: The invention provides compounds and uses thereof in the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy or oxidative stress, and methods of their preparation.

公开(公告)号：US20240279174A1

公开(公告)日：2024-08-22

申请号：US18626187

申请日：2024-04-03

Applicant: Duke University

Inventor： Pei Zhou ,  Jiyong Hong

IPC: C07D209/08 ,  A61K31/495 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/706 ,  C07D213/72 ,  C07D213/89 ,  C07D249/04 ,  C07D261/18 ,  C07D295/26 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07H11/04

CPC classification number: C07D209/08 ,  A61K31/495 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/706 ,  C07D213/72 ,  C07D213/89 ,  C07D249/04 ,  C07D261/18 ,  C07D295/26 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07H11/04

Abstract: Disclosed herein are novel antibiotic compositions and methods of making and using the same. The antibiotic compositions may comprise LPXH-targeting compounds.

公开(公告)号：US20240253023A1

公开(公告)日：2024-08-01

申请号：US11867898

申请日：2007-10-05

Applicant: Christophe Michot ,  Michel Armand ,  Michel Gauthier ,  Yves Choquette

Inventor： Christophe Michot ,  Michel Armand ,  Michel Gauthier ,  Yves Choquette

IPC: B01J31/02 ,  B01J31/04 ,  B01J31/06 ,  B01J31/12 ,  B01J31/18 ,  B01J31/22 ,  C07B37/02 ,  C07B37/12 ,  C07C45/46 ,  C07C45/69 ,  C07C67/00 ,  C07C255/10 ,  C07C255/17 ,  C07C255/27 ,  C07C255/46 ,  C07C255/65 ,  C07C257/14 ,  C07C311/03 ,  C07C311/04 ,  C07C311/09 ,  C07C311/48 ,  C07C317/04 ,  C07C317/08 ,  C07C317/14 ,  C07C317/22 ,  C07C317/24 ,  C07C317/34 ,  C07C317/44 ,  C07D207/452 ,  C07D213/76 ,  C07D219/10 ,  C07D231/18 ,  C07D233/90 ,  C07D239/60 ,  C07D241/42 ,  C07D249/04 ,  C07D249/10 ,  C07D249/12 ,  C07D251/70 ,  C07D277/64 ,  C07D277/82 ,  C07D285/125 ,  C07D285/135 ,  C07D285/15 ,  C07D285/16 ,  C07D303/34 ,  C07D307/54 ,  C07D307/64 ,  C07D311/52 ,  C07D311/58 ,  C07D311/82 ,  C07D319/06 ,  C07D333/16 ,  C07D333/24 ,  C07D405/06 ,  C07D409/12 ,  C07D417/10 ,  C07D417/14 ,  C07F17/02 ,  C08F4/04 ,  C08G65/334 ,  C09B69/00 ,  C09B69/02 ,  C09B69/10 ,  H01B1/12 ,  H01G9/022 ,  H01G11/02 ,  H01G11/62 ,  H01M4/00 ,  H01M4/38 ,  H01M4/58 ,  H01M4/62 ,  H01M6/00 ,  H01M6/16 ,  H01M6/18 ,  H01M10/052 ,  H01M10/0525 ,  H01M10/0565 ,  H01M10/0567 ,  H01M10/0568 ,  G02F1/1516 ,  G02F1/1523 ,  H01M4/02 ,  H01M4/131 ,  H01M4/133 ,  H01M4/134 ,  H01M4/40 ,  H01M4/48 ,  H01M4/485 ,  H01M4/505 ,  H01M4/525 ,  H01M4/60 ,  H01M4/66 ,  H01M6/04

CPC classification number: B01J31/0224 ,  B01J31/0215 ,  B01J31/0222 ,  B01J31/0225 ,  B01J31/0227 ,  B01J31/0235 ,  B01J31/0239 ,  B01J31/0247 ,  B01J31/0251 ,  B01J31/0252 ,  B01J31/0267 ,  B01J31/0271 ,  B01J31/0281 ,  B01J31/0288 ,  B01J31/0289 ,  B01J31/04 ,  B01J31/06 ,  B01J31/068 ,  B01J31/124 ,  B01J31/1815 ,  B01J31/2208 ,  C07B37/02 ,  C07B37/12 ,  C07C45/46 ,  C07C45/69 ,  C07C67/00 ,  C07C255/10 ,  C07C255/17 ,  C07C255/27 ,  C07C255/46 ,  C07C255/65 ,  C07C257/14 ,  C07C311/03 ,  C07C311/04 ,  C07C311/09 ,  C07C311/48 ,  C07C317/04 ,  C07C317/08 ,  C07C317/14 ,  C07C317/22 ,  C07C317/24 ,  C07C317/34 ,  C07C317/44 ,  C07D207/452 ,  C07D213/76 ,  C07D219/10 ,  C07D231/18 ,  C07D233/90 ,  C07D239/60 ,  C07D241/42 ,  C07D249/04 ,  C07D249/10 ,  C07D249/12 ,  C07D251/70 ,  C07D277/64 ,  C07D277/82 ,  C07D285/125 ,  C07D285/135 ,  C07D285/15 ,  C07D285/16 ,  C07D303/34 ,  C07D307/54 ,  C07D307/64 ,  C07D311/52 ,  C07D311/58 ,  C07D311/82 ,  C07D319/06 ,  C07D333/16 ,  C07D333/24 ,  C07D405/06 ,  C07D409/12 ,  C07D417/10 ,  C07D417/14 ,  C07F17/02 ,  C08F4/04 ,  C08G65/3344 ,  C09B69/00 ,  C09B69/02 ,  C09B69/10 ,  H01B1/122 ,  H01B1/128 ,  H01G9/022 ,  H01G11/02 ,  H01G11/62 ,  H01M4/00 ,  H01M4/382 ,  H01M4/5815 ,  H01M4/625 ,  H01M6/00 ,  H01M6/166 ,  H01M6/181 ,  H01M6/183 ,  H01M10/052 ,  H01M10/0525 ,  H01M10/0565 ,  H01M10/0567 ,  H01M10/0568 ,  B01J2231/122 ,  B01J2231/14 ,  B01J2231/326 ,  B01J2231/341 ,  B01J2231/348 ,  B01J2231/4205 ,  B01J2231/543 ,  B01J2531/35 ,  B01J2531/824 ,  C07C2601/10 ,  C07C2602/42 ,  G02F2001/1518 ,  G02F1/1525 ,  H01M4/02 ,  H01M4/131 ,  H01M4/133 ,  H01M4/134 ,  H01M4/405 ,  H01M4/48 ,  H01M4/485 ,  H01M4/505 ,  H01M4/525 ,  H01M4/5825 ,  H01M4/60 ,  H01M4/661 ,  H01M6/04 ,  H01M6/164 ,  H01M6/168 ,  Y02E60/13 ,  Y10S430/127 ,  Y10T29/49108 ,  Y10T428/2918

Abstract: The invention concerns ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention is comprised of an amide or one of its salts, including an anionic portion combined with at least one cationic portion M+m in sufficient numbers to ensure overall electronic neutrality; the compound is further comprised of M as a hydroxonium, a nitrosonium NO+, an ammonium —NH4+, a metallic cation with the valence m, an organic cation with the valence m, or an organometallic cation with the valence m. The anionic portion matches the formula RF—SOx—N−Z, where RF is a perflourinated group, x is 1 or 3, and Z is an electroattractive substituent. The compounds can be used notably for ionic conducting materials, electronic conducting materials, colorants and the catalysis of various chemical reactions.

公开(公告)号：US20240239772A1

公开(公告)日：2024-07-18

申请号：US18556564

申请日：2022-04-21

Applicant: The Cleveland Clinic Foundation

Inventor： Shaun R. Stauffer ,  Sang Hoon Han ,  Alice Hooper ,  Joshua Maw ,  Dhiraj P. Sonawane ,  Matthew R. Porter ,  Steven Martinez ,  Joseph Alvarado ,  Jonathan D. Macdonald

IPC: C07D403/12 ,  A61K31/4192 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/496 ,  A61P31/14 ,  C07D249/04 ,  C07D249/18 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

CPC classification number: C07D403/12 ,  A61K31/4192 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/496 ,  A61P31/14 ,  C07D249/04 ,  C07D249/18 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: Disclosed herein are compounds that inhibit 3C-like protease and inhibit replication of viruses, including SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in a method of treating a viral infection, such as a coronavirus infection.

公开(公告)号：US20240092742A1

公开(公告)日：2024-03-21

申请号：US18500149

申请日：2023-11-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dieter Heindl ,  Hans-Peter Josel ,  Uwe Kobold ,  Christoph Seidel ,  Martin Rempt ,  Andreas Leinenbach ,  Giuseppe Prencipe ,  Silvia Baecher ,  Simon Ferdinand Loibl ,  Anna-Skrollan Geiermann ,  Jelena Milic ,  Nicole Pirkl

IPC: C07D249/06 ,  C07D203/04 ,  C07D249/04 ,  C07D257/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D471/04

CPC classification number: C07D249/06 ,  C07D203/04 ,  C07D249/04 ,  C07D257/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D471/04 ,  G01N30/72

Abstract: The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.

公开(公告)号：US20240067756A1

公开(公告)日：2024-02-29

申请号：US18206937

申请日：2023-06-07

Applicant: YALE UNIVERSITY

Inventor： David Spiegel ,  Ryan Murelli ,  Andrew Zhang

IPC: C07K16/44 ,  A61K9/00 ,  A61K31/4192 ,  A61K45/06 ,  A61K47/54 ,  A61K47/55 ,  A61K47/64 ,  A61K47/68 ,  C07D249/04 ,  C07K16/30

CPC classification number: C07K16/44 ,  A61K9/0019 ,  A61K31/4192 ,  A61K45/06 ,  A61K47/54 ,  A61K47/549 ,  A61K47/55 ,  A61K47/646 ,  A61K47/68 ,  A61K47/6803 ,  A61K47/6869 ,  A61K47/6873 ,  A61K47/6891 ,  C07D249/04 ,  C07K16/3069 ,  C07K2317/31

Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

公开(公告)号：US20230357221A1

公开(公告)日：2023-11-09

申请号：US18343319

申请日：2023-06-28

Applicant: UNIVERSITÉ DE MONTRÉAL

Inventor： Yves GAREAU ,  Stéphane GINGRAS ,  Yves CHANTIGNY ,  Gaoqiang YANG ,  Guy SAUVAGEAU ,  Irène BACCELLI ,  Anne MARINIER

IPC: C07D417/12 ,  C07D249/04 ,  C07D263/32 ,  C07D263/34 ,  C07D277/24 ,  C07D413/12 ,  G01N33/50

CPC classification number: C07D417/12 ,  C07D249/04 ,  C07D263/32 ,  C07D263/34 ,  C07D277/24 ,  C07D413/12 ,  G01N33/5011

Abstract: Heterocyclic compounds of Formula I:




and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.